International guide to drugs for Parkinson's disease.
Identifieur interne : 004744 ( Ncbi/Merge ); précédent : 004743; suivant : 004745International guide to drugs for Parkinson's disease.
Auteurs : W H Oertel [Allemagne] ; R C DodelSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1995.
English descriptors
- KwdEn :
- Adamantane (analogs & derivatives), Adamantane (therapeutic use), Cholinergic Antagonists (therapeutic use), Dopamine Antagonists (therapeutic use), Histamine Antagonists (therapeutic use), Humans, Levodopa (therapeutic use), Monoamine Oxidase Inhibitors (therapeutic use), Parkinson Disease (drug therapy).
- MESH :
- chemical , analogs & derivatives : Adamantane.
- chemical , therapeutic use : Adamantane, Cholinergic Antagonists, Dopamine Antagonists, Histamine Antagonists, Levodopa, Monoamine Oxidase Inhibitors.
- drug therapy : Parkinson Disease.
- Humans.
Abstract
Pharmacotherapy of Parkinson's disease (PD) has become so effective that patients with PD can enjoy a nearly normal life, including travel for several years. The degree of international travel of patients with PD and in particular the recent increased coordination between health systems in the European community call for a detailed information on the different antiparkinsonian drugs available worldwide. To provide an overview for physicians and patients on the diversity of preparations available in the different countries, we compiled the most commonly used substances along with their size of dosage and formula in an international guide to drugs for PD.
DOI: 10.1002/mds.870100202
PubMed: 7753054
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004A18
- to stream PubMed, to step Curation: 004A18
- to stream PubMed, to step Checkpoint: 004970
Links to Exploration step
pubmed:7753054Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">International guide to drugs for Parkinson's disease.</title><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Dodel, R C" sort="Dodel, R C" uniqKey="Dodel R" first="R C" last="Dodel">R C Dodel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:7753054</idno><idno type="pmid">7753054</idno><idno type="doi">10.1002/mds.870100202</idno><idno type="wicri:Area/PubMed/Corpus">004A18</idno><idno type="wicri:Area/PubMed/Curation">004A18</idno><idno type="wicri:Area/PubMed/Checkpoint">004970</idno><idno type="wicri:Area/Ncbi/Merge">004744</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">International guide to drugs for Parkinson's disease.</title><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Dodel, R C" sort="Dodel, R C" uniqKey="Dodel R" first="R C" last="Dodel">R C Dodel</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adamantane (analogs & derivatives)</term><term>Adamantane (therapeutic use)</term><term>Cholinergic Antagonists (therapeutic use)</term><term>Dopamine Antagonists (therapeutic use)</term><term>Histamine Antagonists (therapeutic use)</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adamantane</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adamantane</term><term>Cholinergic Antagonists</term><term>Dopamine Antagonists</term><term>Histamine Antagonists</term><term>Levodopa</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pharmacotherapy of Parkinson's disease (PD) has become so effective that patients with PD can enjoy a nearly normal life, including travel for several years. The degree of international travel of patients with PD and in particular the recent increased coordination between health systems in the European community call for a detailed information on the different antiparkinsonian drugs available worldwide. To provide an overview for physicians and patients on the diversity of preparations available in the different countries, we compiled the most commonly used substances along with their size of dosage and formula in an international guide to drugs for PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7753054</PMID><DateCreated><Year>1995</Year><Month>06</Month><Day>21</Day></DateCreated><DateCompleted><Year>1995</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>1995</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>International guide to drugs for Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>121-31</MedlinePgn></Pagination><Abstract><AbstractText>Pharmacotherapy of Parkinson's disease (PD) has become so effective that patients with PD can enjoy a nearly normal life, including travel for several years. The degree of international travel of patients with PD and in particular the recent increased coordination between health systems in the European community call for a detailed information on the different antiparkinsonian drugs available worldwide. To provide an overview for physicians and patients on the diversity of preparations available in the different countries, we compiled the most commonly used substances along with their size of dosage and formula in an international guide to drugs for PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oertel</LastName><ForeName>W H</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodel</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018680">Cholinergic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006633">Histamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>PJY633525U</RegistryNumber><NameOfSubstance UI="D000218">Adamantane</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000218">Adamantane</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018680">Cholinergic Antagonists</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018492">Dopamine Antagonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006633">Histamine Antagonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008996">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7753054</ArticleId><ArticleId IdType="doi">10.1002/mds.870100202</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li></region><settlement><li>Munich</li></settlement><orgName><li>Université Louis-et-Maximilien de Munich</li></orgName></list><tree><noCountry><name sortKey="Dodel, R C" sort="Dodel, R C" uniqKey="Dodel R" first="R C" last="Dodel">R C Dodel</name></noCountry><country name="Allemagne"><region name="Bavière"><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004744 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004744 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:7753054
|texte= International guide to drugs for Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:7753054" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |